Resources

Get helpful information about MRD and M-inSight®

All
Articles
Documentation
Events
Posters
Publications
decoration
Posters
12/20/2023

Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum - ASH 2023

Posters
12/20/2023

Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight) - ASH 2023

Events
11/22/2023

American Society of Hematology - ASH 2023

Posters
10/05/2023

Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients - IMS 2023

Articles
09/28/2023

Sebia launches M-inSight®, a test for monitoring multiple myeloma patients

Articles
08/28/2023

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021

Articles
08/28/2023

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020

Publications
08/28/2023

Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies - J Proteome Res. 2018

Documentation
08/28/2023

State-specific laboratory certificates and licenses

Documentation
08/28/2023

CAP/CLIA Accreditation for Laboratory Services

Publications
06/29/2023

MRD Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in MM - Blood 2022

Events
06/29/2023

International Myeloma Society 2023

Posters
06/29/2023

An ultra-sensitive method for sequencing and monitoring M-protein in peripheral blood - EMN 2023

Publications
06/29/2023

Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for MRD Monitoring in MM - Clin Chem. 2021

Publications
06/29/2023

Mass Spectrometry for Identification, Monitoring, and MRD Detection of M-Proteins - Clin Chem. 2020

ABOUT M-inSight®

Ultra sensitive, Personalized MRD testing in Blood